<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Kelsey M</submitter><funding>Amgen</funding><funding>NHLBI NIH HHS</funding><funding>National Institutes of Health</funding><pagination>43-50</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9970036</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>153</volume><pubmed_abstract>Lipoprotein (a) [Lp(a)] is associated with increased risk of atherosclerotic cardiovascular disease (ASCVD). As directed therapy for Lp(a) emerges, it is important to understand patterns of Lp(a) testing in routine clinical practice. We set out to characterize Lp(a) testing across a large academic health system. Using electronic health record (EHR) data from 2014 to 2019, we compared patients who underwent Lp(a) testing to date-matched peers who had low density lipoprotein (LDL-C) assessment alone. We analyzed ordering provider characteristics and rates of initiation of new lipid lowering therapy (LLT) within 12 months after testing. Of 1,296 adults with Lp(a) test results, 629 (48.5%) had prior history of ASCVD and 667 (51.4%) did not. Compared with those with LDL-C testing alone, individ</pubmed_abstract><journal>The American journal of cardiology</journal><pubmed_title>Lipoprotein(a) Testing Patterns in a Large Health System.</pubmed_title><pmcid>PMC9970036</pmcid><funding_grant_id>5T32HL069749-17</funding_grant_id><funding_grant_id>T32 HL069749</funding_grant_id><pubmed_authors>Alhanti B</pubmed_authors><pubmed_authors>Kent ST</pubmed_authors><pubmed_authors>Rhodes SL</pubmed_authors><pubmed_authors>Pagidipati N</pubmed_authors><pubmed_authors>Page C</pubmed_authors><pubmed_authors>Peterson E</pubmed_authors><pubmed_authors>Kelsey M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Lipoprotein(a) Testing Patterns in a Large Health System.</name><description>Lipoprotein (a) [Lp(a)] is associated with increased risk of atherosclerotic cardiovascular disease (ASCVD). As directed therapy for Lp(a) emerges, it is important to understand patterns of Lp(a) testing in routine clinical practice. We set out to characterize Lp(a) testing across a large academic health system. Using electronic health record (EHR) data from 2014 to 2019, we compared patients who underwent Lp(a) testing to date-matched peers who had low density lipoprotein (LDL-C) assessment alone. We analyzed ordering provider characteristics and rates of initiation of new lipid lowering therapy (LLT) within 12 months after testing. Of 1,296 adults with Lp(a) test results, 629 (48.5%) had prior history of ASCVD and 667 (51.4%) did not. Compared with those with LDL-C testing alone, individ</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Aug</publication><modification>2025-04-04T00:36:12.751Z</modification><creation>2025-04-04T00:36:12.751Z</creation></dates><accession>S-EPMC9970036</accession><cross_references><pubmed>34210501</pubmed><doi>10.1016/j.amjcard.2021.05.018</doi></cross_references></HashMap>